Wilmington, DE -- (SBWIRE) -- 12/16/2013 -- Equity Profile Report expands its NASDAQ Active Stock Weekly Watch List adding Geron Corporation (NASDAQ:GERN) and Cree, Inc. (NASDAQ:CREE).
Geron Corporation (NASDAQ:GERN) a clinical stage biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies closed down in its previous session (-0.21%) on 3,524,921 shares traded after TheStreet Quant Ratings rated Geron Corporation as a sell. Geron Corporation (NASDAQ:GERN) is currently down (-40.82%) from its recent 52-week high which has prompted Equity Profile Report to add the stock to their NASDAQ Active Stock Watch List.
Click Here to find out what other Investors are saying about Geron Corporation (NASDAQ:GERN)
Cree, Inc. (NASDAQ:CREE) a company that develops, manufactures, and sells lighting-class light emitting diode, lighting, and semiconductor products for power and radio-frequency applications in the United States, China, Europe, South Korea, Japan, Malaysia, and Taiwan closed up in its previous session (+0.27%) on 1,082,588 shares traded. Cree, Inc. (NASDAQ:CREE) is currently up (+80.59%) from its recent 52-week low which has prompted Equity Profile Report to add the stock to their NASDAQ Active Stock Watch List.
Click Here to find out what other Investors are saying about Cree, Inc. (NASDAQ:CREE)
Equityprofilereport.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities.
Through a vast network of IR professionals Equityprofilereport.com is often aware of several large investor awareness campaigns being deployed.
Timing is important when trading Small Caps and Penny Stocks.
Simply sign up for free and start receiving exclusive alerts.
Subscribe Here: http://www.Equityprofilereport.com
Equityprofilereport.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit Equityprofilereport.com website, for complete risks and disclosures.
Equity Profile Report